# Measuring effects of morphine withdrawal on dopaminergic salience coding across the striatum

> **NIH NIH K00** · VANDERBILT UNIVERSITY · 2024 · $84,969

## Abstract

DESCRIPTION (provided by applicant): Opioid abuse remains a costly epidemic in the US, 
prompting research into new and effective interventions to curb addiction-like behavior. Amongst the 
therapeutic characteristics of opioids, their associated withdrawal effects are substantial and 
recognized to contribute to development of abuse and relapse. While acute somatic withdrawal 
symptoms are relatively well characterized, their prolonged affective counterparts are less understood. 
Regulating a broad array of affective behaviors, the mesolimbic dopamine (DA) system has been 
demonstrated as both necessary and sufficient for reward-related behavior towards opioids and 
withdrawal- related negative affect, with a canonical hypodopaminergic state following opioid 
dependence at least partially responsible for drug craving and relapse vulnerability. Despite this, 
limitations of previous studies concerning heterogeneity of mesolimbic circuitry and a shortage of 
assessments of opioid-induced long-term changes to motivated behavior and subsequent drug intake 
following dependence have stifled clear demonstrations of protracted motivational dysfunction and 
detection of underlying mechanism for the associated hypodopaminergic state. Growing evidence 
indicates that cannabinoid (CB) signaling is highly influential in regulating mesoaccumbal dopamine 
and opioid systems, including dopamine and opioid control of reinforcement, and that CB-based 
therapies may hold efficacy in treating negative affective states during acute/somatic withdrawal and 
perhaps opioid intake. Despite these promising data, data regarding how CB signaling is altered during 
opioid withdrawal and whether CB-therapies are efficacious in countering dependence-related changes 
in motivation for and intake of opioids with more protracted withdrawal are almost non-existent. This 
proposal builds off my research to date demonstrating that 1) morphine dependence promotes a long-lasting elevation in GABAA- mediated inhibitory tone specific to DA neurons in the lateral ventral 
tegmental area projecting to the lateral nucleus accumbens shell (latVTA-latShell), 2) prior dependence 
increases motivation for and intake of morphine, and 3) elevations in GABA signaling align with an 
apparent tolerance to CB1-induced disinhibition of lateral VTA DA firing. In Aim2/Exp1, I will utilize ex 
vivo slice electrophysiology to assess alterations in synaptic strength and CB-dependent regulation of 
GABAergic afferents from the rostromedial tegmental nucleus (RMTg) to latVTA- latShell DA cells. 
Behavior studies in Aim2/Exp2 will extend upon data demonstrating increased effort-based motivated 
responding for morphine under protracted withdrawal conditions by measuring cannabinoid-induced 
alteration of this effect. Completing these experiments will support my research development by adding 
technical skills in more sophisticated electrophysiology and behavioral approaches. Further, results will 
fill crit...

## Key facts

- **NIH application ID:** 10829472
- **Project number:** 5K00DA059288-03
- **Recipient organization:** VANDERBILT UNIVERSITY
- **Principal Investigator:** Devan Marc Gomez
- **Activity code:** K00 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $84,969
- **Award type:** 5
- **Project period:** 2021-07-01 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10829472

## Citation

> US National Institutes of Health, RePORTER application 10829472, Measuring effects of morphine withdrawal on dopaminergic salience coding across the striatum (5K00DA059288-03). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10829472. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
